ReviewRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2023
Insights for COVID-19 in 2023.
Review in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 80 citations in OpenAlex.
- Effectiveness of CoronaVac in a pioneer risk-based allocation clinical trial during the COVID-19 pandemic.PloS one · 2026Trial
- A Retrospective Analysis of Changes in Respiratory Pathogens During the Influenza Season Before and After the Relaxation of Non-Pharmaceutical Intervention Policies.Health science reports · 2025Article
- COVID-19 Induces Greater NLRP3 Inflammasome Activation in Obese Patients than Other Chronic Illnesses: A Case-Control Study.International journal of molecular sciences · 2025Article
- Neural mechanisms of cognitive conflict: processing COVID-19 vaccine misinformation.Frontiers in neuroscience · 2025Article
- New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons.Enfermedades infecciosas y microbiologia clinica · 2025Review
- Complex evaluation of coagulation, fibrinolysis, and inflammatory cytokines in SARS-CoV-2 infected pregnant women: a prospective, case-control study.Frontiers in immunology · 2025Observational
- Association of plasma microRNAs with COVID-19 severity and outcome.Journal, genetic engineering & biotechnology · 2024Article
- Enhanced predictability and interpretability of COVID-19 severity based on SARS-CoV-2 genomic diversity: a comprehensive study encompassing four years of data.Scientific reports · 2024Article
- Influence of SARS-CoV-2 variants on COVID-19 epidemiological and clinical profiles: a comparative analysis of two waves of cases.Virology journal · 2024Observational
- Characterization of the symmetrical benzimidazole twin drug TL1228: the role as viral entry inhibitor for fighting COVID-19.Biology direct · 2024Article
- Effectiveness of an online multimodal rehabilitation program in long COVID patients: a randomized clinical trial.Archives of public health = Archives belges de sante publique · 2024Article
- Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study.BMC infectious diseases · 2024Article
- Exploring the potential mechanisms of Danshen against COVID-19 via network pharmacology analysis and molecular docking.Scientific reports · 2024Article
- CT pulmonary angiography in the emergency department: utilization and positivity rates during various phases of the COVID-19 pandemic.Emergency radiology · 2024Article
- Factors Associated with All-Cause 30-Day Mortality in Indonesian Inpatient COVID-19 Patients at Cipto Mangunkusumo National General Hospital.Journal of clinical medicine · 2024Article
- Blood Count and Renal Functionality Assessments in the Emergency Section Disclose Morbidity and Mortality in Omicron COVID-19 Patients: A Retrospective Study.Clinics and practice · 2024Article
- Critically ill children with SARS-COV-2 Omicron infection at a national children medical center, Guangdong, China.BMC pediatrics · 2024Article
- HB-EGF Plasmatic Level Contributes to the Development of Early Risk Prediction Nomogram for Severe COVID-19 Cases.Biomedicines · 2024Article
- Identification of SARS-CoV-2 in urban rodents from Southern Mexico City at the beginning of the COVID-19 pandemic.Revista do Instituto de Medicina Tropical de Sao Paulo · 2024Article
- A Three-Year Cross-Sectional Analysis of Depression, Anxiety, and Quality of Life in Patients with Post-COVID-19 Syndrome.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Predictions for a near end of the pandemic by the World Health Organization should be interpreted with caution. Current evidence indicates that the efficacy of a fourth dose of classical mRNA vaccines (BT162b2 or mRNA-1273) is low and short-lived in preventing SARS-CoV-2 infection in its predominant variant (Omicron). However, its efficacy is high against severe symptomatic infection, hospitalization and death. The new vaccines being introduced are bivalent and active against the Omicron variants. Potential new vaccines to be introduced in the coming year include a vaccine based on a recombinant protein that emulates the receptor binding domain of the Spike protein under development by the Spanish company Hipra, as well as vaccines for nasal or oral administration. Available information suggests that vaccines against COVID-19 can be administered in association with influenza vaccination without particular complications. New drugs against COVID-19, both antiviral and anti-inflammatory, are under investigation, but this does not seem to be the case with monoclonal antibodies. The indication to use masks in some circumstances will be maintained next year in view of the accumulation of scientific data on their efficacy. Finally, the long COVID or Post-COVID syndrome may continue to affect a very high proportion of patients who have had the disease, requiring combined diagnostic and therapeutic resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.